Afternoon workshop: 13:30-17:00
Transferability and Relevance of Cost-Effectiveness Data Between Countries
Silvia Evers, PhD, LLM, Professor Public Health Technology Assessment, Department of Health Services Research, Maastricht University, Maastricht, the Netherlands
Manuela A. Joore, PhD, Professor of Health Technology Assessment & Decision Making, Maastricht University Medical Center+, Maastricht, the Netherlands
Although the number of countries requiring an economic dossier as part of the reimbursement process is increasing, not every country is able to conduct economic evaluations for every innovation. However, national decision makers require country-specific or region-specific estimates on health care costs and patient outcome. More and more, they are only willing to accept foreign or international analyses when these are transferable to their own specific decision making context. But little guidance on how to do this exists. This course starts with a discussion of factors that make economic evidence more difficult to transfer from one country to other countries than clinical evidence. Then we will review the methods that have been presented to assess the transferability of foreign cost, effects and cost-effectiveness estimates and their pros and cons. This topic will be practically covered in a case (working in small groups), that will subsequently be discussed. Methods available mostly focus on trial-based economic evaluation, however we will present transferring issues encountered when assessing model-based economic evaluations as well. Finally, we will discuss the transferability of health state valuations based on the EQ5-D instrument and the transferability of lost productivity data. Please note: The statistical methods to analyse multinational trial data and to transfer these data to a specific country are beyond the scope of this course.